Compugen Stock Price, News & Analysis (NASDAQ:CGEN)

$3.25 0.50 (18.18 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$3.25
Today's Range$2.65 - $3.65
52-Week Range$2.25 - $5.40
Volume716,097 shs
Average Volume185,683 shs
Market Capitalization$154.48 million
P/E Ratio-4.58
Dividend YieldN/A
Beta0.57

About Compugen (NASDAQ:CGEN)

Compugen logoCompugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CGEN
CUSIPN/A
Phone+972-3-7658585

Debt

Debt-to-Equity RatioN/A
Current Ratio6.73%
Quick Ratio6.73%

Price-To-Earnings

Trailing P/E Ratio-4.57746478873239
Forward P/E Ratio-4.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00
Price / Sales234.05
Cash FlowN/A
Price / CashN/A
Book Value$1.25 per share
Price / Book2.60

Profitability

Trailing EPS($0.71)
Net Income$-31,500,000.00
Net MarginsN/A
Return on Equity-70.91%
Return on Assets-60.92%

Miscellaneous

Employees98
Outstanding Shares51,130,000

Compugen (NASDAQ:CGEN) Frequently Asked Questions

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.19). View Compugen's Earnings History.

When will Compugen make its next earnings announcement?

Compugen is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Compugen.

Where is Compugen's stock going? Where will Compugen's stock price be in 2018?

1 Wall Street analysts have issued twelve-month price objectives for Compugen's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Compugen's share price to reach $14.00 in the next year. View Analyst Ratings for Compugen.

What are Wall Street analysts saying about Compugen stock?

Here are some recent quotes from research analysts about Compugen stock:

  • 1. According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (1/9/2018)
  • 2. FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:

  • Paul Jai Sekhri, Chairman of the Board (Age 59)
  • Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Ari Krashin, Chief Financial Officer (Age 42)
  • Zurit Levine Ph.D., Vice President - Research and Discovery (Age 47)
  • John Hunter, Vice President - Antibody Research & Development (Age 52)
  • Dov Hershberg, Director (Age 75)
  • Michal Preminger Ph.D., Director
  • Yair Aharonowitz Ph.D., Independent External Director (Age 74)
  • Ruth Arnon, Independent Director (Age 81)
  • Arie Ovadia, Independent External Director (Age 68)

Who owns Compugen stock?

Compugen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Benjamin F. Edwards & Company Inc. (0.17%). View Institutional Ownership Trends for Compugen.

Who bought Compugen stock? Who is buying Compugen stock?

Compugen's stock was bought by a variety of institutional investors in the last quarter, including Benjamin F. Edwards & Company Inc.. View Insider Buying and Selling for Compugen.

How do I buy Compugen stock?

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of Compugen stock can currently be purchased for approximately $3.25.

How big of a company is Compugen?

Compugen has a market capitalization of $154.48 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-31,500,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. Compugen employs 98 workers across the globe.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center, 26 Harokmim St. Bldg D, HOLON, 5885849, Israel. The biotechnology company can be reached via phone at +972-3-7658585 or via email at [email protected]


MarketBeat Community Rating for Compugen (CGEN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Compugen (NASDAQ:CGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.00$14.00$14.00$14.00
Price Target Upside: 225.58% upside225.58% upside225.58% upside225.58% upside

Compugen (NASDAQ:CGEN) Consensus Price Target History

Price Target History for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ:CGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017FBR & CoSet Price TargetBuy$14.00HighView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
2/11/2016Jefferies GroupReiterated RatingBuy$11.00 -> $9.00N/AView Rating Details
2/1/2016OppenheimerReiterated RatingBuyN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Compugen (NASDAQ:CGEN) Earnings History and Estimates Chart

Earnings by Quarter for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ CGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018        
11/7/2017Q3 2017($0.19)($0.19)ViewN/AView Earnings Details
8/2/20176/30/2017($0.17)($0.18)$0.21 millionViewListenView Earnings Details
5/9/20173/31/2017($0.18)($0.17)$0.06 millionViewListenView Earnings Details
2/15/2017Q416($0.18)($0.17)$0.13 million$0.05 millionViewListenView Earnings Details
11/7/2016Q316($0.14)($0.15)$0.41 million$0.07 millionViewN/AView Earnings Details
8/2/2016Q116($0.17)($0.13)$0.11 million$0.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.16)($0.17)$0.12 million$0.09 millionViewListenView Earnings Details
2/9/2016Q415($0.11)($0.01)$3.33 million$8.30 millionViewN/AView Earnings Details
11/3/2015Q315($0.15)($0.13)$0.92 million$0.23 millionViewN/AView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.58 million$0.22 millionViewN/AView Earnings Details
5/5/2015Q115($0.13)($0.12)$1.88 million$0.51 millionViewN/AView Earnings Details
2/10/2015Q414($0.08)($0.03)$3.70 million$6.60 millionViewN/AView Earnings Details
10/29/2014Q314($0.11)($0.11)$1.90 million$1.70 millionViewN/AView Earnings Details
8/6/2014Q214($0.10)($0.07)$1.85 million$2.00 millionViewN/AView Earnings Details
5/19/2014Q114($0.11)($0.04)$0.16 million$2.10 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)$0.13 million$1.80 millionViewN/AView Earnings Details
10/29/2013Q313($0.12)$0.11 million$1.60 millionViewN/AView Earnings Details
8/2/2013Q2 2013($0.09)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.09)ViewN/AView Earnings Details
2/20/2013Q4 2012($0.15)ViewN/AView Earnings Details
11/5/2012Q312($0.10)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/1/2012Q1 2012($0.12)ViewN/AView Earnings Details
2/7/2012Q4 2011($0.13)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.10)ViewN/AView Earnings Details
8/2/2011Q2 2011($0.06)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.06)ViewN/AView Earnings Details
2/15/2011Q4 2010($0.06)ViewN/AView Earnings Details
10/26/2010Q3 2010($0.05)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.06)($0.03)ViewN/AView Earnings Details
4/27/2010Q1 2010($0.05)($0.08)ViewN/AView Earnings Details
2/9/2010Q4 2009($0.08)($0.07)ViewN/AView Earnings Details
10/27/2009Q3 2009($0.07)($0.06)ViewN/AView Earnings Details
7/28/2009Q2 2009$0.08ViewN/AView Earnings Details
5/12/2009Q1 2009($0.08)ViewN/AView Earnings Details
2/11/2009Q4 2008($0.13)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.12)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.10)ViewN/AView Earnings Details
5/14/2008Q1 2008($0.09)ViewN/AView Earnings Details
2/19/2008Q4 2007($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Compugen (NASDAQ:CGEN) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.73 EPS
Next Year EPS Consensus Estimate: $-0.82 EPS

Dividends

Dividend History for Compugen (NASDAQ:CGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Compugen (NASDAQ CGEN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Compugen (NASDAQ CGEN) News Headlines

Source:
DateHeadline
Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid TumorsCompugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors
finance.yahoo.com - January 18 at 11:00 AM
Compugen (CGEN) Lifted to "Hold" at Zacks Investment ResearchCompugen (CGEN) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 9 at 7:12 PM
Contrasting NewLink Genetics (NLNK) & Compugen (CGEN)Contrasting NewLink Genetics (NLNK) & Compugen (CGEN)
www.americanbankingnews.com - January 7 at 1:10 AM
Compugen Announces Presentations at Three Upcoming Cancer ... - PR Newswire (press release)Compugen Announces Presentations at Three Upcoming Cancer ... - PR Newswire (press release)
www.prnewswire.com - January 2 at 9:57 AM
Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy ConferencesCompugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences
finance.yahoo.com - January 2 at 9:57 AM
FibroGen (FGEN) versus Compugen (CGEN) Head to Head SurveyFibroGen (FGEN) versus Compugen (CGEN) Head to Head Survey
www.americanbankingnews.com - December 31 at 1:28 PM
What You Must Know About Compugen Ltd’s (NASDAQ:CGEN) Financial HealthWhat You Must Know About Compugen Ltd’s (NASDAQ:CGEN) Financial Health
finance.yahoo.com - December 19 at 10:05 AM
Contrasting Ohr Pharmaceuticals (OHRP) & Compugen (CGEN)Contrasting Ohr Pharmaceuticals (OHRP) & Compugen (CGEN)
www.americanbankingnews.com - December 10 at 7:50 PM
Financial Review: Compugen (CGEN) & Ohr Pharmaceuticals (OHRP)Financial Review: Compugen (CGEN) & Ohr Pharmaceuticals (OHRP)
www.americanbankingnews.com - December 9 at 1:18 PM
How Compugen Ltd’s (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too?How Compugen Ltd’s (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too?
finance.yahoo.com - December 1 at 5:20 PM
Compugen (CGEN) Downgraded by Zacks Investment ResearchCompugen (CGEN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 29 at 6:04 PM
Financial Review: Compugen (CGEN) & Concert Pharmaceuticals (CNCE)Financial Review: Compugen (CGEN) & Concert Pharmaceuticals (CNCE)
www.americanbankingnews.com - November 26 at 5:10 AM
Is It Too Late To Buy Compugen Ltd (CGEN)?Is It Too Late To Buy Compugen Ltd (CGEN)?
finance.yahoo.com - November 16 at 12:45 PM
Head-To-Head Survey: Compugen (CGEN) versus Quintiles Transitional Holdings (Q)Head-To-Head Survey: Compugen (CGEN) versus Quintiles Transitional Holdings (Q)
www.americanbankingnews.com - November 8 at 9:31 AM
Compugens (CGEN) CEO Anat Cohen-Dayag on Q3 2017 Results - Earnings Call TranscriptCompugen's (CGEN) CEO Anat Cohen-Dayag on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 8:08 PM
Compugen Reports Third Quarter 2017 ResultsCompugen Reports Third Quarter 2017 Results
finance.yahoo.com - November 7 at 8:08 PM
Compugen reports 3Q lossCompugen reports 3Q loss
finance.yahoo.com - November 7 at 8:08 PM
Compugen Ltd. to Host Earnings CallCompugen Ltd. to Host Earnings Call
finance.yahoo.com - November 7 at 8:08 PM
Compugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal AntibodyCompugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody
finance.yahoo.com - November 6 at 6:18 PM
ArQule (ARQL) vs. Compugen (CGEN) Head to Head ComparisonArQule (ARQL) vs. Compugen (CGEN) Head to Head Comparison
www.americanbankingnews.com - November 5 at 9:26 AM
Compugen (CGEN) & Its Competitors Head to Head AnalysisCompugen (CGEN) & Its Competitors Head to Head Analysis
www.americanbankingnews.com - November 3 at 5:32 AM
Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology TargetsCompugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets
finance.yahoo.com - November 2 at 5:56 PM
Compugen Ltd. (CGEN) Scheduled to Post Quarterly Earnings on TuesdayCompugen Ltd. (CGEN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 1:56 PM
Compugen to Present at the Annual Meeting of the Society for ... - PR Newswire (press release)Compugen to Present at the Annual Meeting of the Society for ... - PR Newswire (press release)
www.prnewswire.com - October 28 at 12:54 AM
Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET - PR Newswire (press release)Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET - PR Newswire (press release)
www.prnewswire.com - October 26 at 8:33 AM
Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next MonthCompugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month
finance.yahoo.com - October 26 at 8:33 AM
Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ETCompugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET
finance.yahoo.com - October 25 at 6:36 PM
Contrasting Compugen (CGEN) and The CompetitionContrasting Compugen (CGEN) and The Competition
www.americanbankingnews.com - October 22 at 12:24 AM
Compugens CGEN-15032 shows potential as immuno-suppressive target in research study, shares ahead 8% premarket - Seeking AlphaCompugen's CGEN-15032 shows potential as immuno-suppressive target in research study, shares ahead 8% premarket - Seeking Alpha
seekingalpha.com - October 11 at 6:39 PM
Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032
finance.yahoo.com - October 11 at 6:39 PM
Compugen (CGEN) Says New Immunomodulatory Target Demonstrates Potential for First-in-Class Cancer Therapy - StreetInsider.comCompugen (CGEN) Says New Immunomodulatory Target Demonstrates Potential for First-in-Class Cancer Therapy - StreetInsider.com
www.streetinsider.com - October 9 at 5:47 PM
A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer TherapyA New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy
finance.yahoo.com - October 9 at 5:47 PM
Flexion Shares Continue Rise After FDA Approval -- Biotech MoversFlexion Shares Continue Rise After FDA Approval -- Biotech Movers
finance.yahoo.com - October 9 at 5:47 PM
Compugen Ltd (CGEN): How Does It Impact Your Portfolio?Compugen Ltd (CGEN): How Does It Impact Your Portfolio?
finance.yahoo.com - October 2 at 4:28 PM
Financial Review: Incyte Corporation (INCY) versus Compugen (CGEN)Financial Review: Incyte Corporation (INCY) versus Compugen (CGEN)
www.americanbankingnews.com - September 16 at 2:30 AM
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next MonthCompugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
finance.yahoo.com - August 7 at 5:32 PM
Q3 2017 EPS Estimates for Compugen Ltd. (NASDAQ:CGEN) Reduced by Jefferies GroupQ3 2017 EPS Estimates for Compugen Ltd. (NASDAQ:CGEN) Reduced by Jefferies Group
www.americanbankingnews.com - August 4 at 8:30 AM
Compugen Ltd. (CGEN) Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPSCompugen Ltd. (CGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - August 3 at 8:08 PM
Compugen (CGEN) Announces Paul Sekhri as New Chairman of the Board - StreetInsider.comCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board - StreetInsider.com
www.streetinsider.com - August 3 at 6:36 PM
Compugens (CGEN) CEO Anat Cohen-Dayag on Q2 2017 Results - Earnings Call TranscriptCompugen's (CGEN) CEO Anat Cohen-Dayag on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 2 at 5:54 PM
Compugen (CGEN) Announces Paul Sekhri as New Chairman of the BoardCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board
www.streetinsider.com - August 2 at 5:54 PM
Compugen Reports Second Quarter 2017 ResultsCompugen Reports Second Quarter 2017 Results
finance.yahoo.com - August 2 at 5:54 PM
Compugen Welcomes Paul Sekhri as its New Chairman of the BoardCompugen Welcomes Paul Sekhri as its New Chairman of the Board
finance.yahoo.com - August 2 at 5:54 PM
Compugen reports 2Q lossCompugen reports 2Q loss
finance.yahoo.com - August 2 at 5:54 PM
 Brokerages Expect Compugen Ltd. (CGEN) Will Announce Earnings of -$0.17 Per Share Brokerages Expect Compugen Ltd. (CGEN) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - July 28 at 10:24 PM
BRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncologyBRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
www.reuters.com - July 28 at 2:38 AM
Compugen (CGEN) Reprts Updates to Collaborative Activities with Bayer in Immuno-OncologyCompugen (CGEN) Reprts Updates to Collaborative Activities with Bayer in Immuno-Oncology
www.streetinsider.com - July 28 at 2:38 AM
BUZZ-US STOCKS ON THE MOVE- Boeing, AMD, Akamai, Corning - NasdaqBUZZ-US STOCKS ON THE MOVE- Boeing, AMD, Akamai, Corning - Nasdaq
www.nasdaq.com - July 27 at 9:37 PM
Compugen Ltd. (CGEN) Set to Announce Quarterly Earnings on WednesdayCompugen Ltd. (CGEN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 27 at 9:59 AM
Compugen (CGEN) Reprts Updates to Collaborative Activities with ... - StreetInsider.comCompugen (CGEN) Reprts Updates to Collaborative Activities with ... - StreetInsider.com
www.streetinsider.com - July 26 at 5:39 PM

SEC Filings

Compugen (NASDAQ:CGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Compugen (NASDAQ:CGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Compugen (NASDAQ CGEN) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.